Kodiak Sciences (KOD) Expected to Announce Earnings on Thursday

Kodiak Sciences (NASDAQ:KOD) is expected to be announcing its Q3 2026 results after the market closes on Thursday, November 12th. Analysts expect Kodiak Sciences to announce earnings of ($1.06) per share for the quarter. Individuals may review the information on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 12, 2026 at 4:00 PM ET.

Kodiak Sciences (NASDAQ:KOD) last released its quarterly earnings results on Thursday, August 13th. The company reported ($1.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.96) by ($0.09). On average, analysts expect Kodiak Sciences to post ($3.97) EPS for the current fiscal year and ($4.14) EPS for the next fiscal year.

Kodiak Sciences Trading Down 0.4%

Shares of KOD stock opened at $98.51 on Thursday. The business’s 50 day moving average is $67.32 and its two-hundred day moving average is $43.00. The company has a market capitalization of $6.19 billion, a P/E ratio of -23.51 and a beta of 2.02. Kodiak Sciences has a 12-month low of $15.83 and a 12-month high of $104.00.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. The Goldman Sachs Group started coverage on shares of Kodiak Sciences in a research note on Wednesday, September 30th. They set a “neutral” rating and a $103.00 price objective for the company. HC Wainwright increased their price objective on shares of Kodiak Sciences from $96.00 to $126.00 and gave the company a “buy” rating in a report on Monday, October 12th. UBS Group raised their target price on shares of Kodiak Sciences from $80.00 to $120.00 and gave the stock a “buy” rating in a research note on Monday, September 28th. Weiss Ratings cut Kodiak Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, October 6th. Finally, Wall Street Zen upgraded Kodiak Sciences from a “strong sell” rating to a “sell” rating in a report on Sunday, October 4th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $104.71.

Insider Buying and Selling

In other Kodiak Sciences news, Director Bros. Advisors Lp Baker purchased 33,726 shares of the firm’s stock in a transaction dated Tuesday, September 29th. The shares were acquired at an average price of $85.05 per share, with a total value of $2,868,396.30. Following the purchase, the director directly owned 20,191,214 shares in the company, valued at approximately $1,717,262,750.70. This trade represents a 0.17% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders acquired a total of 1,941,755 shares of company stock valued at $156,986,026 in the last quarter. 44.40% of the stock is owned by insiders.

About Kodiak Sciences

Kodiak Sciences Inc (NASDAQ: KOD) is a clinical-stage biopharmaceutical company focused on developing treatments for retinal diseases. The company’s research centers on therapies designed to address conditions that can cause vision loss, including diabetic macular edema, neovascular age-related macular degeneration and retinal vein occlusion.

Kodiak’s proprietary Antibody Biopolymer Conjugate platform is designed to combine the targeting capabilities of antibody-based medicines with a biodegradable polymer intended to extend the duration of treatment in the eye.